Marie Frimodt-Møller

​Senior Researcher, Ph.D
Diabetes Complications Research


Phone: +45 30913042

Research area

1. Diabetic Nephropathy

  • Clinical studies on biomarkes and screeningmethods to identify persons at increased risk for cardiovascular disease and development and progression of diabetic kidney disease.
  • Clinical interventionstudies with medicine aimed at preventing diabetic kidney disease and cardiovascular disease.

2. Hypertension and arterial stiffness

  • Clinical intervention studies of resistant hypertension
  • Clinical studies with focus on arterial stiffness in relation to intervention and risk stratification.

Current research

 1. PRIORITY – Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy In TYpe 2 diabetic patients with normoalbuminuria
Aim:  To examine
• If urine-proteomics can predict development of diabetic kidney disease in a kohort of app. 2000 patients with type 2 diabetes.
• If treatment with spironolakton can prevent development of diabetic kidney disease.
Prof.Dr.Christian Delles, Glasgow University, Scotland
Prof. Dr. Heiko von der Leyen, Hannover Clinical

Trial Center,  Germany
18 study sites in Europe
2. PRIORITY – Diabetic distress
Aim: To examine to which extent the classification of patients in high-or low risk for kidney disease affects diabetic distress.
Lene Joensen, Health Promotion, SDCC

3. PROTON-PeRsOnalising Treatment Of diabetic Nephropathy – consortium grant no. NNF14SA0003

Prof.Dr.Per-Henrik Groop, Helsinki, Finland
Hiddo Lambers Heerspink, University Medical Center Groningen, The Netherlands
Prof.Dr.Andrzej Krolewski, Joslin Diabetes Center, Boston, USA

4. PROTON – cross sectional study
PROTON-partners as mentioned
Prof.´s Dr.Oluf Borbye Pedersen and Torben Hansen, Center of Metabolism, Copenhagen University
Markku Lehto
Harald Mischak, Mosaiques Diagnostics, Hannover, Germany.

5. PROTON– Authonomic Neuropathy
Aim: To examine the relation between authonomic dysfunction and different degrees of diabetic kidney disease as well as its relation to markers of microcirculation, urine proteomics and established cardiovascular biomarkers for endothelial dysfunction.
Prof.Luciano Bernardi and Marco Bordino, Padua University, Italy

6. PROTON – MicroREx
Aim:  To examine the reproducibility and examination conditions of a new device the GlycoCheck ® to evaluate the microcirculation. 
Prof. Hiddo Lambers Heerspink, University Medical Center Groningen, Holland

Aim: To examine the effect of treatment with SGLT-2 inhibitors (Dapagliflozin) on urinary albumin excretion in patients with type 2 diabetes.
Magnus Jensen,  Flemming Olsen, Dept. Of cardiology, Gentofte Hospital.
Harald Mischak, Mosaiques Diagnostics, Hannover.

8. C3M in type 2 diabetes
Formål: To examine the relation between the fibrosis marker C3M and cardiovascular disease and decline in kidney function in type 2 diabetes.
Federica Genovese and Daniel Guldager Kring Rasmussen, Nordic Bio


9. B

‘Formål: To examine the effect of treatment with the new neprilysin-inhibitors BI 690517 on resistant hypertension in diabetic nephropathy in terms of safety and tolerability. 
Boehringer Ingelheim

10. RenaKVit-study
Aim: To examine the effect of 12 months of treatment with vitamin K2 on arterial stiffness and bone structure in dialysis patients.
Karin Schousboe, Peter Marckman, dep.of Nephrology, RoskildeHospital and Ditte Hansen, dep. of nephrology, Herlev Hospital.

Responsible editor